These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24325578)

  • 21. In vitro and in vivo comparison of [³H](+)-PHNO and [³H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D₃ from D₂ receptor sites.
    Kiss B; Horti F; Bobok A
    Synapse; 2011 Jun; 65(6):467-78. PubMed ID: 20936685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
    Gopishetty B; Zhang S; Kharkar PS; Antonio T; Reith M; Dutta AK
    Bioorg Med Chem; 2013 Jun; 21(11):3164-74. PubMed ID: 23623679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.
    Caravaggio F; Kegeles LS; Wilson AA; Remington G; Borlido C; Mamo DC; Graff-Guerrero A
    Synapse; 2016 Nov; 70(11):453-60. PubMed ID: 27341789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective agonists for dopamine/neurotensin receptor heterodimers.
    Koschatzky S; Gmeiner P
    ChemMedChem; 2012 Mar; 7(3):509-14. PubMed ID: 22213714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
    Blagg J; Allerton CM; Batchelor DV; Baxter AD; Burring DJ; Carr CL; Cook AS; Nichols CL; Phipps J; Sanderson VG; Verrier H; Wong S
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6691-6. PubMed ID: 17976986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.
    Caravaggio F; Nakajima S; Borlido C; Remington G; Gerretsen P; Wilson A; Houle S; Menon M; Mamo D; Graff-Guerrero A
    Neuropsychopharmacology; 2014 Nov; 39(12):2769-76. PubMed ID: 24874713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans.
    Seeman P
    Synapse; 2012 Jan; 66(1):88-93. PubMed ID: 21954082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.
    Vessotskie JM; Kung MP; Chumpradit S; Romaniello G; McElgin W; Frederick D; Malison RT; Kung HF
    J Nucl Med; 1995 Jul; 36(7):1282-8. PubMed ID: 7790957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride.
    Booze RM; Wallace DR
    Synapse; 1995 Jan; 19(1):1-13. PubMed ID: 7709338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.
    McCormick PN; Kapur S; Seeman P; Wilson AA
    Nucl Med Biol; 2008 Jan; 35(1):11-7. PubMed ID: 18158938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain.
    Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G
    Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.
    Seeman P; Guan HC
    Synapse; 2009 Aug; 63(8):705-9. PubMed ID: 19391149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
    Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of (125)I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors.
    Luedtke RR; Freeman RA; Boundy VA; Martin MW; Huang Y; Mach RH
    Synapse; 2000 Dec; 38(4):438-49. PubMed ID: 11044891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated Dopamine D
    Gaiser EC; Gallezot JD; Worhunsky PD; Jastreboff AM; Pittman B; Kantrovitz L; Angarita GA; Cosgrove KP; Potenza MN; Malison RT; Carson RE; Matuskey D
    Neuropsychopharmacology; 2016 Dec; 41(13):3042-3050. PubMed ID: 27374277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography.
    Vasdev N; Natesan S; Galineau L; Garcia A; Stableford WT; McCormick P; Seeman P; Houle S; Wilson AA
    Synapse; 2006 Sep; 60(4):314-8. PubMed ID: 16786538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships between dopamine D2/3 receptor availability and social-environmental factors in humans.
    Calakos KC; Rusowicz A; Pittman B; Gallezot JD; Potenza MN; Cosgrove KP; Matuskey D
    Neurosci Lett; 2022 Feb; 771():136463. PubMed ID: 35051435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.